{"page":{"totalFilteredElements":348},"studies":[{"active":true,"description":"A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and \nDexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab,&#160; Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell \nTransplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are \nTransplant Eligible","eudractNumber":"2021-003284-10","id":9102,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05257083","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-06-01T12:31:22+02:00","shortTitle":"CARTITUDE-6, EMN28/68284528MMY3005","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus<br />Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in<br />Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small<br />Lymphocytic Lymphoma","eudractNumber":"2024-517131-52-00","id":11276,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"del (Deletions)","id":"mt_247"},{"name":"del (17p)","id":"mt_23"},{"name":"TP53","id":"mt_24"}],"nctNumber":"NCT06943872","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2025-10-31T08:53:02+01:00","shortTitle":"CELESTIAL-RR CLL (BGB-11417-303)","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"<p class=\"MsoNormal\" align=\"left\" style=\"margin:0cm 0cm .0001pt;line-height:13.4pt;\">Kontinuierliches vs. intermittierendes\n  Neuromonitoring zur Reduktion der passageren&#160;Recurrenspareserate in der Schilddr&#252;senchirurgie &#8211; eine prospektive, randomisierte,&#160;kontrollierte, multizentrische klinische Studie (CITY-Studie)</p><p class=\"MsoNormal\" align=\"left\" style=\"margin:0cm 0cm .0001pt;line-height:13.4pt;\">DRKS00033520</p>\n  \n \n<br />","eudractNumber":null,"id":9864,"indications":[{"id":"sch","name":"Schilddrüsenkarzinom"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-07-15T09:08:10+02:00","shortTitle":"CITY Trial","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Langzeitnachbeobachtung von Patienten mit CLL, B-PLL, T-PLL, SLL, T/NK-LGL, HCL und Richter Transformation","eudractNumber":null,"id":1659,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT02863692","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2012-07-01T10:53:05+02:00","shortTitle":"CLL-Registry [DCLLSG Register]","therapeutical":false,"therapyLines":[]},{"active":true,"description":"EINE PROSPEKTIVE, OFFENE, MULTIZENTRISCHE, RANDOMISIERTE PHASE-3-STUDIE MIT ACALABRUTINIB, OBINUTUZUMAB UND VENETOCLAX (GAVE) IM VERGLEICH ZU OBINUTUZUMAB UND VENETOCLAX (GVE) BEI ZUVOR UNBEHANDELTEN PATIENTEN MIT HOCHRISIKO (17P-DELETION, TP53-MUTATION ODER KOMPLEXEM KARYOTYP) CHRONISCHER LYMPHATISCHER LEUK&#196;MIE (CLL): CLL-16 STUDIE DER DCLLSG","eudractNumber":"2020-004360-26","id":8660,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"del (Deletions)","id":"mt_247"},{"name":"del (17p)","id":"mt_23"},{"name":"TP53","id":"mt_24"}],"nctNumber":"NCT05197192","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2022-10-25T14:28:21+02:00","shortTitle":"CLL16","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ \nsmall lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for \nadjustment of treatment duration to improve outcomes","eudractNumber":"2023-510294-34","id":11270,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-08-11T11:42:59+02:00","shortTitle":"CLL18 / MOIRAI-TRIAL","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A prospective observational trial to assess treatment sequences and factors that impact<br />overall survival in patients with chronic lymphocytic leukaemia (CLL) treated within first-line<br />studies of the GCLLSG","eudractNumber":null,"id":12152,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06792994","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-06-22T10:53:24+02:00","shortTitle":"CLL2000","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Beobachtungsstudie zum Verlauf der CML unter den neuen Erstlinientherapien","eudractNumber":null,"id":3460,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"}],"mutations":[{"name":"ABL","id":"mt_203"},{"name":"bcr-abl","id":"mt_57"}],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2016-01-01T11:09:29+01:00","shortTitle":"CML VI - Registerstudie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p class=\"MsoNormal\" align=\"center\" style=\"text-align:left;margin:12pt 0cm 6pt;\">NCT-COMPASS:\ndeCOMPressing stomA und zweistufige elektive Resektion vs. Notfall-Resektion\nbei Patienten mit linksseitigem obstruktivem Dickdarmkrebs</p><p class=\"MsoNormal\" align=\"center\" style=\"margin:12pt 0cm 6pt;text-align:left;\">DRKS00031827</p><p class=\"MsoNormal\" align=\"center\" style=\"text-align:left;margin:12pt 0cm 6pt;\"><br /></p>","eudractNumber":null,"id":9179,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-01-31T10:54:20+01:00","shortTitle":"COMPASS","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Ivosidenib in combination with Azacitidine as first-line treatment for adult patients with newly diagnosed AML with an IDH1 R132 mutation who are not eligible to receive standard induction chemotherapy: A prospective, longitudinal, multicenter, observational study in Germany.","eudractNumber":null,"id":10267,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":"NCT06181734","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-09-13T09:23:35+02:00","shortTitle":"CONFIDHENCE","therapeutical":false,"therapyLines":[]}]}